Study on Effect and Adverse Reaction of Huaiqihuang Granule Assisted Beliuzumab in SLE Treatment Among Children
Objective To investigate the efficacy of Huaiqihuang Granules assisted Beliuzumab in the treatment of children with systemic lupus erythematosus(SLE)and its adverse reaction.Methods A total of 100 children with SLE,who were admit-ted to Nanyang Central Hospital between July 2020 and July 2023,were selected.They were randomly assigned to control group A(n=33),control group B(n=33),and study group(n=34)according to simple randomization method.All three groups re-ceived conventional treatment.In addition,control group A was treated with belimumab,control group B was treated with Hua-iqihuang Granules,and the study group was treated with Huaiqihuang Granules+belimumab.All patients were treated for 24 weeks.The therapeutic effects and symptom improvement of the three groups were compared,as well as the levels of serum im-mune indicators[immunoglobulin G(IgG),complement C3,complement C4,CD3+,CD4+/CD8+],inflammatory factors[inter-leukin-2(IL-2),erythrocyte sedimentation rate(ESR),C-reactive protein(CRP)],microRNA-200(miR-200),microRNA-335(miR-335)before and after treatment.The adverse reactions during treatment were statistically compared among the three groups.Results The difference in total effective rate between the study group(97.06％),control group A(81.82％)and control group B(78.79％)was not significant(all P＞0.05).The study group showed a shorter time for skin lesion reduction,proteinu-ria decrease,pain relief,and body temperature drop compared to the control A and B groups(all P＜0.05).After 24 weeks of treatment,the levels of serum complement C3,complement C4,peripheral blood CD3+,and CD4+/CD8+in the study group were higher than those in control group A and B.Meanwhile,the level of IgG was lower(all P＜0.05).After 24 weeks of treat-ment,the levels of serum IL-2,CRP,and peripheral blood ESR in the study group were lower than those in control group A and B(all P＜0.05).After 24 weeks of treatment,the serum miR-200 level in the study group was higher than that in control group A and B,while the serum miR-335 level was lower than that in control group A and B(all P＜0.05).The incidences of adverse reactions in the study group,control A group and control B group were 8.82％,12.12％and 6.06％,respectively,with no sig-nificant difference between groups(all P＞0.05).Conclusion Huaiqihuang Granules assisted belimumab demonstrates signifi-cant efficacy in the treatment of SLE in children.It can effectively enhance immune function,and exhibit good safety profile.
万方数据
维普
